# A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

> **NCT00373425** · PHASE3 · COMPLETED · sponsor: **OSI Pharmaceuticals** · enrollment: 1252 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00373425
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2013-04
- **Final completion:** 2014-06
- **Target enrollment:** 1252 (ACTUAL)
- **Last updated:** 2015-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373425, "A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00373425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*